Noteworthy ETF Inflows: DFAC, CVX, WFC, MRK
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 28 2025
0mins
Should l Buy MRK?
Source: NASDAQ.COM
DFAC Stock Performance: DFAC's stock has a 52-week range with a low of $28.39 and a high of $36.66, currently trading at $34.37, which is useful for technical analysis when compared to the 200-day moving average.
ETFs Trading Dynamics: Exchange traded funds (ETFs) operate like stocks but involve buying and selling units that can be created or destroyed based on investor demand, impacting the underlying holdings significantly during notable inflows or outflows.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.680
Low
95.00
Averages
119.53
High
139.00
Current: 115.680
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
MERCK & CO INC ANTICIPATES $5.8 BILLION CHARGE OF APPROXIMATELY $2.35 PER SHARE IN Q2 AND FY2026, WITH DEAL CLOSURE EXPECTED IN Q2 2026
Merck & Co. Deal Closure: Merck & Co. is expected to finalize a significant deal in the second quarter of 2026.
Financial Implications: The deal is projected to incur a charge of approximately $2.35 per share in the second quarter and will impact the financial results for the fiscal year 2026.
See More
MERCK & CO INC - TRANSACTION VALUED AT APPROXIMATELY $5.7 BILLION NET OF CASH, REFLECTING A 31% PREMIUM OVER 60-DAY VWAP AS OF MARCH 24, 2026
- Deal Overview: Merck & Co has announced a deal valued at approximately $5.7 billion.
- Premium Details: The deal includes a 31% premium based on the 60-day volume-weighted average price (VWAP) as of March 24, 2026.
See More
Merck & Co Inc Acquires Terns Pharmaceuticals at $53.00 Per Share, Valuing Equity at $6.7 Billion
- Acquisition Announcement: Merck & Co. has announced its intention to acquire Terns Pharmaceuticals for $53.00 per share.
- Valuation Details: The total equity value of the acquisition is estimated at $6.7 billion.
See More
Merck to Purchase Terns Pharmaceuticals, Enhancing Hematology Pipeline with TERN-701, a New Treatment for Chronic Myeloid Leukemia (CML)
Merck's Acquisition: Merck has acquired Terns Pharmaceuticals, Inc. to enhance its hematology pipeline.
Focus on Chronic Myeloid Leukemia: The acquisition includes Terns' novel candidate, TERN-701, which is aimed at treating chronic myeloid leukemia (CML).
See More
MERCK CLOSES IN ON $6BN BIOTECH ACQUISITION TO ENHANCE CANCER DRUG PORTFOLIO - FT
- Merck's Acquisition: Merck is set to acquire a biotechnology company for approximately $6 billion to enhance its cancer drug pipeline.
- Strategic Focus: This deal reflects Merck's commitment to expanding its portfolio in oncology and strengthening its position in the competitive cancer treatment market.
See More
Merck to Acquire Terns Pharmaceuticals for $6.7 Billion
- Acquisition Agreement: Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, totaling approximately $6.7 billion, indicating Merck's strategic intent to expand its oncology portfolio.
- Financial Impact: The transaction is expected to be classified as an asset acquisition, with an anticipated close in Q2 2026, resulting in a charge of about $5.8 billion or approximately $2.35 per share, which will affect both GAAP and non-GAAP results for the second quarter and full year 2026.
- Product Line Expansion: Merck's CEO Robert Davis highlighted that this acquisition enhances the company's presence in hematology, particularly with TERN-701, a potential best-in-class treatment for certain chronic myeloid leukemia patients, thereby strengthening its market position.
- Positive Market Reaction: In pre-market trading on NasdaqGS, Terns shares rose by 5.08% to $52.54, reflecting a positive market response to the acquisition and potentially indicating investor confidence in Merck's future growth prospects.
See More
MERCK & CO INC ANTICIPATES $5.8 BILLION CHARGE OF APPROXIMATELY $2.35 PER SHARE IN Q2 AND FY2026, WITH DEAL CLOSURE EXPECTED IN Q2 2026
Merck & Co. Deal Closure: Merck & Co. is expected to finalize a significant deal in the second quarter of 2026.
Financial Implications: The deal is projected to incur a charge of approximately $2.35 per share in the second quarter and will impact the financial results for the fiscal year 2026.
See More
MERCK & CO INC - TRANSACTION VALUED AT APPROXIMATELY $5.7 BILLION NET OF CASH, REFLECTING A 31% PREMIUM OVER 60-DAY VWAP AS OF MARCH 24, 2026
- Deal Overview: Merck & Co has announced a deal valued at approximately $5.7 billion.
- Premium Details: The deal includes a 31% premium based on the 60-day volume-weighted average price (VWAP) as of March 24, 2026.
See More
Merck & Co Inc Acquires Terns Pharmaceuticals at $53.00 Per Share, Valuing Equity at $6.7 Billion
- Acquisition Announcement: Merck & Co. has announced its intention to acquire Terns Pharmaceuticals for $53.00 per share.
- Valuation Details: The total equity value of the acquisition is estimated at $6.7 billion.
See More
Merck to Purchase Terns Pharmaceuticals, Enhancing Hematology Pipeline with TERN-701, a New Treatment for Chronic Myeloid Leukemia (CML)
Merck's Acquisition: Merck has acquired Terns Pharmaceuticals, Inc. to enhance its hematology pipeline.
Focus on Chronic Myeloid Leukemia: The acquisition includes Terns' novel candidate, TERN-701, which is aimed at treating chronic myeloid leukemia (CML).
See More
MERCK CLOSES IN ON $6BN BIOTECH ACQUISITION TO ENHANCE CANCER DRUG PORTFOLIO - FT
- Merck's Acquisition: Merck is set to acquire a biotechnology company for approximately $6 billion to enhance its cancer drug pipeline.
- Strategic Focus: This deal reflects Merck's commitment to expanding its portfolio in oncology and strengthening its position in the competitive cancer treatment market.
See More
Merck to Acquire Terns Pharmaceuticals for $6.7 Billion
- Acquisition Agreement: Merck has entered into a definitive agreement to acquire Terns Pharmaceuticals for $53.00 per share in cash, totaling approximately $6.7 billion, indicating Merck's strategic intent to expand its oncology portfolio.
- Financial Impact: The transaction is expected to be classified as an asset acquisition, with an anticipated close in Q2 2026, resulting in a charge of about $5.8 billion or approximately $2.35 per share, which will affect both GAAP and non-GAAP results for the second quarter and full year 2026.
- Product Line Expansion: Merck's CEO Robert Davis highlighted that this acquisition enhances the company's presence in hematology, particularly with TERN-701, a potential best-in-class treatment for certain chronic myeloid leukemia patients, thereby strengthening its market position.
- Positive Market Reaction: In pre-market trading on NasdaqGS, Terns shares rose by 5.08% to $52.54, reflecting a positive market response to the acquisition and potentially indicating investor confidence in Merck's future growth prospects.
See More
